Tumor vascular targeting

Drugs of the Future

Volumn 31, Issue 10, 2006, Pages 901-913

  Mårlind, Jessica ^a   Pisoni, Ivan ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b Philogen SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOKINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INTEGRIN; INTERLEUKIN 2; LAR; LIPOCORTIN 1; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; PEGAPTANIB; PEPTIDE; PHOTOSENSITIZING AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOLIGAND; TENASCIN; THROMBOPLASTIN; TOSITUMOMAB I 131; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BIOINFORMATICS; BIOTINYLATION; CANCER; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ACTIVITY; DRUG TARGETING; EX VIVO STUDY; HUMAN; IN VIVO STUDY; LYMPHOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSCRIPTOMICS; TUMOR; VASCULAR TUMOR;

EID: 33846062854     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.10.1032054     Document Type: Review

References (140)

1. Bosslet, K., Straub, R., Blumrich, M. et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998, 58: 1195-201.
2. Ramachandran, C., Melnick, S.J. Multidrug resistance in human tumors-Molecular diagnosis and clinical significance. Mol Diagn 1999, 4: 81-94.
3. Tozer, G.M., Ameer-Beg, S.M., Baker, J. et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 2005, 57: 135-52.
4. Tozer, G.M., Lewis, S., Michalowski, A., Aber, V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 1990, 61: 250-7.
5. Helmlinger, G., Yuan, F., Dellian, M., Jain, R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 1997, 3: 177-82.
6. Denekamp, J., Hobson, B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 1982, 46: 711-20.
7. Toyokuni, S., Okamoto, K., Yodoi, J., Hiai, H. Persistent oxidative stress in cancer. FEBS Lett 1995, 358: 1-3.
8. Brown, N.S., Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: Its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3: 323-7.
9. Clarke, M.S., West, D.C. The identification of proliferation and tumour-induced proteins in human endothelial cells: A possible target for tumour therapy. Electrophoresis 1991, 12: 500-8.
10. Borsi, L., Carnemolla, B., Castellani, P. et al. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 1987, 104: 595-600.
11. Mutuberria, R., Satijn, S., Huijbers, A. et al. Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Meth 2004, 287: 31-47.
12. Adams, M.D., Kerlavage, A.R., Fleischmann, R.D. et al. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature 1995, 377: 3-174.
13. Huminiecki, L., Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res 2000, 10: 1796-806.
14. Huminiecki, L., Gorn, M., Suchting, S., Poulsom, R., Bicknell, R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 2002, 79: 547-52.
15. Sullivan, D.C., Huminiecki, L., Moore, J.W. et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 2003, 278: 47079-88.
16. Velculescu, V.E., Zhang, L., Vogelstein, B., Kinzler, K.W. Serial analysis of gene expression. Science 1995, 270: 484-7.
17. St. Croix, B., Rago, C., Velculescu, V. et al. Genes expressed in human tumor endothelium. Science 2000, 289: 1197-202.
18. Carson-Walter, E.B., Watkins, D.N., Nanda, A., Vogelstein, B., Kinzler, K.W., St. Croix, B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001, 61: 6649-55.
19. Nanda, A., St. Croix, B. Tumor endothelial markers: New targets for cancer therapy. Curr Opin Oncol 2004, 16: 44-9.
20. Christian, S., Ahorn, H., Koehler, A. et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001, 276: 7408-14.
21. MacFadyen, J.R., Haworth, O., Roberston, D. et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005, 579: 2569-75.
22. Duesbery, N.S., Resau, J., Webb, C.P. et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 2001, 98: 4089-94.
23. Durr, E., Yu, J., Krasinska, K.M. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 2004, 22: 985-92.
24. Oh, P., Li, Y, Yu, J. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429: 629-35.
25. Rybak, J.N., Ettorre, A., Kaissling, B., Giavazzi, R., Neri, D., Elia, G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Meth 2005, 2: 291-8.
26. Rybak, J.N., Scheurer, S.B., Neri, D., Elia, G. Purification of biotinylated proteins on streptavidin resin: A protocol for quantitative elution. Proteomics 2004, 4: 2296-9.
27. Roesli, C., Elia, G., Neri, D. Two-dimensional mass spectrometric mapping. Curr Opin Chem Biol 2006, 10: 35-41.
28. Castronovo, V., Waltregny, D., Kischel, P. et al. Accessible proteins expressed in kidney cancer. Submitted 2006.
29. Zardi, L., Carnemolla, B., Siri, A. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6: 2337-42.
30. Carnemolla, B., Balza, E., Siri, A. et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989, 108: 1139-48.
31. Pini, A., Viti, F., Santucci, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273: 21769-76.
32. Carnemolla, B., Neri, D., Castellani, P. et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996, 68: 397-405.
33. Neri, D., Carnemolla, B., Nissim, A. et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997, 15: 1271-5.
34. Borsi, L., Balza, E., Bestagno, M. et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102: 75-85.
35. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999, 59: 347-52.
36. Tarli, L., Balza, E., Viti, F. et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94: 192-8.
37. Demartis, S., Tarli, L., Borsi, L. Zardi, L., Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001, 28: 534-9.
38. Santimaria, M., Moscatelli, G., Viale, G.L. et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9: 571-9.
39. Fattorusso, R., Pellecchia, M., Viti, F., Neri, P., Neri, D., Wuthrich, K. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure Fold Des 1999, 7: 381-90.
40. Borsi, L., Carnemolla, B., Nicolo, G., Spina, B., Tanara, B., Zardi, L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992, 52: 688-92.
41. Carnemolla, B., Castellani, P., Ponassi, M. et al. Identification of a gliobiastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999, 154: 1345-52.
42. Riva, P., Franceschi, G., Frattarelli, M. et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin Cancer Res 1999, 5: 3275s-80s.
43. Paganelli, G., Grana, C., Chinol, M. et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999, 26: 348-57.
44. Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3: 391-400.
45. Carmeliet, P. Angiogenesis in health and disease. Nat Med 2003, 9: 653-60.
46. He, Y., Karpanen, T., Alitalo, K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004, 1654: 3-12.
47. Streit, M., Detmar, M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003, 22: 3172-9.
48. Brekken, R.A., Huang, X., King, S.W., Thorpe, P.E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998, 58: 1952-9.
49. Brekken, R.A., Overholser, J.P., Stastny, V.A., Waltenberger, J., Minna, J.D., Thorpe, P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60: 5117-24.
50. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004, 25: 581-611.
51. Prewett, M., Huber, J., Li, Y. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59: 5209-18.
52. Halin, C., Niesner, U., Villani, M.E., Zardi, L., Neri, D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002, 102: 109-16.
53. Gutheil, J.C., Campbell, T.N., Pierce, P.R. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000, 6: 3056-61.
54. Posey, J.A., Khazaeli, M.B., DelGrosso, A. et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001, 16: 125-32.
55. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., McDonald, D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163: 1801-15.
56. Sipkins, D.A., Cheresh, D.A., Kazemi, M.R., Nevin, L.M., Bednarski, M.D., Li, K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998, 4: 623-6.
57. Bostwick, D.G., Grignon, D.J., Hammond, M.E. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124: 995-1000.
58. Liu, H., Moy, P., Kim, S. et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997, 57: 3629-34.
59. Chang, S.S., Reuter, V.E., Heston, W.D., Bander, N.H., Grauer, L.S., Gaudin, P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59: 3192-8.
60. Bander, N.H., Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., Goldsmith, S.J. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003, 30: 667-76.
61. Milowsky, M.I., Nanus, D.M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S.J., Bander, N.H. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004, 22:2522-31.
62. Bander, N.H., Milowsky, M.I., Nanus, D.M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23: 4591-601.
63. Li, Y., Tian, Z., Rizvi, S.M., Bander, N.H., Allen, B.J. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 2002, 5: 36-46.
64. Kennel, S.J., Mirzadeh, S., Eckelman, W.C. et al. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat Res 2002, 157: 633-41.
65. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-7.
66. Jones, P.T., Dear, P.H., Foote, J.. Neuberger, M.S., Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321: 522-5.
67. Zou, Y.R., Gu, H., Rajewsky, K. Generation of a mouse strain that produces immunoglobulin kappa chains with human constant regions. Science 1993, 262: 1271-4.
68. Winter, G., Griffiths, A.D., Hawkins, R.E., Hoogenboom, H.R. Making antibodies by phage display technology. Annu Rev Immunol 1994, 12: 433-55.
69. McCafferty, J., Griffiths, A.D., Winter, G., Chiswell, D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348: 552-4.
70. Silacci, M., Brack, S., Schirru, G. et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005, 5: 2340-50.
71. Schaffitzel, C., Hanes, J., Jermutus, L., Pluckthun, A. Ribosome display: An in vitro method for selection and evolution of antibodies from libraries. J Immunol Methods 1999, 231: 119-35.
72. Brekke, O.H., Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003, 2: 52-62.
73. Nimjee, S.M., Rusconi, C.P., Sullenger, B.A. Aptamers: An emerging class of therapeutics. Annu Rev Med 2005, 56: 555-83.
74. Vater, A., Klussmann, S. Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. Curr Opin Drug Discov Devel 2003, 6: 253-61.
75. Doggrell, S.A. Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother 2005, 6: 1421-3.
76. Hicke, B.J., Stephens, A.W., Gould, T. et al. Tumor targeting by an aptamer. J Nucl Med 2006, 47: 668-78.
77. Felici, F., Luzzago, A., Monaci, P., Nicosia, A., Sollazzo, M., Traboni, C. Peptide and protein display on the surface of filamentous bacteriophage. Biotechnol Annu Rev 1995, 1: 149-83.
78. Terskikh, A.V., Le Doussal, J.M., Crameri, R., Fisch, I., Mach, J.P., Kajava, A.V. "Peptabody": A new type of high avidity binding protein. Proc Natl Acad Sci USA 1997, 94: 1663-8.
79. Wrighton, N.C., Balasubramanian, P., Barbone, P.P. et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 1997, 15: 1261-5.
80. Mattheakis, L.C., Bhatt, R.R., Dower, W.J. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994, 91: 9022-6.
81. Collins, J., Horn, N., Wadenback, J., Szardenings, M. Cosmix-plexing; A novel recombinatorial approach for evolutionary selection from combinatorial libraries. J Biotechnol 2001, 74: 317-38.
82. Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R., Ruoslahti, E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998, 102: 430-7.
83. Pasqualini, R., Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380: 364-6.
84. Kowalski, J., Henze, M., Schuhmacher, J., Macke, H.R., Hofmann, M., Haberkorn, U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003, 5: 42-8.
85. Behr, T.M., Gotthardt, M., Barth, A., Behe, M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001, 45: 189-200.
86. Ginj, M., Maecke, H.R. Radiometallo-labeled peptides in tumor diagnosis and therapy. Met Ions Biol Syst 2004, 42: 109-42.
87. Chen, X., Park, R., Hou, Y. et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004, 31: 1081-9.
88. Okarvi, S.M., al-Jammaz, I. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res 2003, 23: 2745-50.
89. Maeshima, Y., Sudhakar, A., Lively, J.C. et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295: 140-3.
90. Tan, M., Lan, K.H., Yao, J. et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 2006, 66: 3764-72.
91. Arkin, M.R., Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Drug Discov 2004, 3: 301-17.
92. Melkko, S., Dumelin, C.E., Scheuermann, J., Neri, D. On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides. Chem Biol 2006, 13: 225-31.
93. Shuker, S.B., Hajduk, P.J., Meadows, R.P., Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274: 1531-4.
94. Ramstrom, O., Lehn, J.M. Drug discovery by dynamic combinatorial libraries. Nat Rev Drug Discov 2002, 1: 26-36.
95. Erlanson, D.A., Lam, J.W., Wiesmann, C. et al. In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol 2003, 21: 308-14.
96. Melkko, S., Scheuermann, J., Dumelin, C.E., Neri, D. Encoded self-assembling chemical libraries. Nat Biotechnol 2004, 22: 568-74.
97. Dumelin, C.E., Scheuermann, J., Melkko, S., Neri, D. Selection of streptavidin binders from a DNA-encoded chemical library. Bioconjug Chem 2006, 17: 366-70.
98. Grabmaier, K., A de Weijert, M.C., Verhaegh, G.W., Schalken, J.A., Oosterwijk, E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23: 5624-31.
99. Muckenschnabel, I., Falchetto, R., Mayr, L.M., Filipuzzi, I. SpeedScreen: Label-free liquid chromatography-mass spectrometry-based high-throughput screening for the discovery of orphan protein ligands. Anal Biochem 2004, 324: 241-9.
100. Gartner, Z.J., Tse, B.N., Grubina, R., Doyon, J.B., Snyder, T.M., Liu, D.R. DNA-templated organic synthesis and selection of a library of macrocycles. Science 2004, 305: 1601-5.
101. Niesner, U., Halin, C., Lozzi, L. et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002, 13: 729-36.
102. Castellani, P., Dorcaratto, A., Pau, A. et al. The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir (Wien) 2000, 142: 277-82.
103. Brack, S.S., Dinkelborg, L.M., Neri, D. Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med MoI Imaging 2004, 31: 1327-41.
104. Wan, S., Parrish, J.A., Anderson, R.R., Madden, M. Transmittance of nonionizing radiation in human tissues. Photochem Photobiol 1981, 34: 679-81.
105. Birchler, M., Neri, G., Tarli, L., Halin, C., Viti, F., Neri, D., Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 1999, 231: 239-48.
106. Ntziachristos, V., Yodh, A.G., Schnall, M., Chance, B., Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA 2000, 97: 2767-72.
107. Josephson, L., Groman, E., Weissleder, R. Contrast agents for magnetic resonance imaging of the liver. Targeted Diagn Ther 1991, 4: 163-87.
108. Weller, G.E., Wong, M.K., Modzelewski, R.A. et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 2005, 65: 533-9.
109. Schirner, M., Menrad, A., Stephens, A., Frenzel, T., Hauff, P., Licha, K. Molecular imaging of tumor angiogenesis. Ann NY Acad Sci 2004, 1014: 67-75.
110. Shields, R.L., Namenuk, A.K., Hong, K. et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001, 276: 6591-604.
111. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H., Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999, 17: 176-80.
112. Huston, J.S., Levinson, D., Mudgett-Hunter, M. et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988, 85: 5879-83.
113. Birchler, M., Viti, F., Zardi, L., Spiess, B., Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999, 17: 984-8.
114. Fabbrini, M., Trachsel, E., Soldani, P. et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006, 118: 1805-13.
115. Berndorff, D., Borkowski, S., Sieger, S. et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005, 11: 7053s-63s.
116. Marty, C., Odermatt, B., Schott, H. et al. Cytotoxic targeting of FQ teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 2002, 87: 106-12.
117. Marty, C., Schwendener, R.A. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol Med 2005, 109: 389-402.
118. Nilsson, F., Kosmehl, H., Zardi, L., Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61: 711-6.
119. Thorpe, P.E., Ran, S. Tumor infarction by targeting tissue factor to tumor vasculature. Cancer J 2000, 6(Suppl. 3): S237-44.
120. Carnemolla, B., Borsi, L, Balza, E. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99: 1659-65.
121. Halin, C., Rondini, S., Nilsson, F. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002, 20: 264-9.
122. Borsi, L., Balza, E., Carnemolla, B. et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003, 102: 4384-92.
123. Ebbinghaus, C., Ronca, R., Kaspar, M. et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005, 116: 304-13.
124. Heinis, C., Alessi, P., Neri, D. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme pro-drug therapy. Biochemistry 2004, 43: 6293-303.
125. Melkko, S., Halin, C., Borsi, L., Zardi, L., Neri, D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys 2002, 54: 1485-90.
126. Fishman, M., Seigne, J. Immunotherapy of metastatic renal cell cancer. Cancer Control 2002, 9: 293-304.
127. Eggermont, A.M., Schraffordt Koops, H., Lienard, D. et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996, 14: 2653-65.
128. Colombo, M.P., Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002, 13: 155-68.
129. Davis, C.B., Gillies, S.D. Immunocytokines: Amplification of anti-cancer immunity. Cancer Immunol Immunother 2003, 52: 297-308.
130. Menrad, A., Menssen, H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005, 9: 491-500.
131. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., Thorpe, P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275: 547-50.
132. van Dongen, G.A., Visser, G.W., Vrouenraets, M.B. Photosensitizer- antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 2004, 56: 31-52.
133. Fabbrini, M., Trachsel, E., Soldani, P. et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006, 118(7): 1805-13.
134. Stern, M., Herrmann, R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol 2005, 54: 11-29.
135. Adams, G.P., Shaller, C.C., Dadachova, E. et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004, 64: 6200-6.
136. Borjesson, P.K., Postema, E.J., de Bree, R. et al. Radioimmunodetection and radioimmunotherapy of head and neck cancer. Oral Oncol 2004, 40: 761-72.
137. Borjesson, P.K., Postema, E.J., Roos, J.C. et al. Phase / therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003, 9: 3961S-72S.
138. Erickson, H.K., Park, P.U., Widdison, W.C. et al. Antibody- maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006, 66: 4426-33.
139. Smith, LM., Nesterova, A., Alley, S.C., Torgov, M.Y., Carter, P.J. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 2006, 5: 1474-82.
140. Austin, C.D., Wen, X., Gazzard, L., Nelson, C., Scheller, R.H., Scales, S.J. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA 2005, 102: 17987-92.